In short: White Falcon Capital (Partner Strategy): the compilation's most self-critical pitch. "The biggest detractor this quarter was EPAM… as the saying goes there is sometimes no difference between being early and being wrong." The stock "has now de-rated to approximately 4x EV/EBITDA and 7x P/E" on a net-cash balance sheet, because "AI is evolving so rapidly that many enterprises are delaying large digital transformation projects." Their claim is that this is "a timing rather than a structural issue": "the real bottleneck is no longer model development but enterprise deployment and integration," driving investment in forward-deployed engineering teams — "EPAM has spent decades building exactly this type of organization." The strategic-value marker: peer Nagarro agreed to be acquired at "approximately 9.1x EV/EBITDA and 1.3x revenue — more than double EPAM's valuation."
EPAM supplies software engineers to large companies rebuilding their technology. It has been the worst position in White Falcon's portfolio, and they say so plainly, quoting the line about there being no difference between being early and being wrong.
The shares have fallen to about four times earnings before interest, tax and depreciation, with more cash than debt. The cause is straightforward: firms are postponing big technology projects until they understand what AI will change.
White Falcon's argument is that the delay is temporary and the direction is favourable. The bottleneck in AI has moved from building models to actually getting them working inside real companies with old systems and messy data — which is precisely the kind of engineering EPAM has spent decades organising. Their evidence that the market is mispricing it: a smaller rival was just bought at more than double EPAM's valuation.
Full passage: premium transcript (PDF).
In short: Second-worst performer at -27.0% — an IT-services name in the same AI-disruption crossfire as the Paychex spotlight, though the post draws no link. Performance line only.
In short: Third-worst YTD performer at -44.0% (5-yr CAGR -24.5%, 10-yr +4.7%) and April's worst at -15.9%. Performance table only; no view.
In short: Worst performer of the month at -15.9%. Performance table only. Framed positively by the section's standing line: "the cheaper we can buy great companies, the better."
In short: Ninth-worst watchlist performer at −31.9% year to date (−18.2% over five years). Not rated Buy; no commentary.
Nothing matches this filter.
Verbatim excerpts from the public transcripts (auto-pulled at each mention's timestamp, lightly cleaned). Timestamps link into the video; "source page" opens that commentator's full analysis at this row. Click a mention's header line to expand it (one open at a time). For personal study — not investment advice.